Identificación de mujeres de alto riesgo | 19 MAY 14

Cáncer de mama

Cómo se puede identificar a las mujeres con alto riesgo de cáncer de mama. ¿Qué rol tienen los estudios genéticos y la cirugía o quimioterapia preventivas? Una exhaustiva guía de acción para el médico práctico.
Autor/a: Dres. Anne C Armstrong, Gareth D Evans. BMJ 2014;348:g2756
INDICE:  1.  | 2. Referencias
Referencias


Referencias

1 Cancer Research UK. Breast cancer incidence statistics. 2012. www.cancerresearchuk. org/cancer-info/cancerstats/types/breast/incidence/#risk.
2 Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and nvironmental factors in the UK in 2010. Summary and conclusions. Br J Cancer 2011;105(S2):S77-81.
3 Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. Association between common risk factors and molecular subtypes in breast cancer patients. Breast 2013;22:344-50.
4 National Institute for Health and Care Excellence. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. (Clinical guideline 164.) 2013. http://guidance.nice.org.uk/CG164.
5 Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89.
6 Rubinstein WS. Hereditary breast cancer in Jews. Fam Cancer 2004;3:249-57.
7 Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin’s lymphoma in England and Wales: a national cohort study. J Clin Oncol 2012;30:2745-52.
8 Lalloo F, Evans DG. Familial breast cancer. Clin Genet 2012;82:105-14.
9 Evans DG, Ingham RL. Reduced life expectancy seen in hereditary diseases which predispose to early-onset tumors. Appl Clin Genet 2013;6:53-61.
10 Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2002;72:1117-30.
11 Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
12 Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008;8:155.
13 Papelard H, de Bock GH, van Eijk R, Vliet Vlieland TP, Cornelisse CJ, Devilee P, et al. Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer 2000;83:719-24.
14 Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Navanlinna H, et al.Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012;21:134-47.
15 Harris H, Nippert I, Julian-Reynier C, Schmidtke J, van Asperen C, Gadzicki D, et al.
Familial breast cancer: is it time to move from a reactive to a proactive role? Fam Cancer 2011;10:501-3.
16 Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2005;23:1111-30.
17 Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, et al. Predicting the Likeliho od of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008:45:425-31.
18 Evans DG, Lalloo F, Cramer A, Jones E, Knox F, Amir E, et al. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009;46:811-7.
19 Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778-86.
20 Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009;101:205-9.
21 Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
22 Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78.
23 Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148:671-9.
24 Ralleigh G, Given-Wilson R. Breast cancer risk and possible screening strategies for young women following supradiaphragmatic irradiation for Hodgkin’s disease. Clin Radiol 2004;59:647-50.
25 Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-62.
26 Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 2013;24:2029-35.
27 Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lallo F, et al. Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Res Treat 2013;142:611-8.
28 Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 2013;140:135-42.
29 Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast  cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 2014;348:g226.
30 Hallowell N, Baylock B, Heiniger L, Butow PN, Patel D, Meiser B, et al. Looking different, feeling different women’s reactions to risk-reducing breast and ovarian surgery. Fam Cancer 2012;11:215-24.
31 Montgomery LL, Tran KN, Heelan MC, Van Zee KJ, Massie MJ, Payne DK, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 1999;6:546-52.
32 Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-7.
33 Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, et al. Breast cancer incidence after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Cancer Prev Res (Phila) 2012;5:1291-7.
34 Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
35 Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:7804-10.
36 Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381:1827-34.
37 Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2013;383:1041-8.
38 Moyer VA. Medications for risk reduction of primary breast cancer in women: US Preventative Services Task Force recommendation statement. Ann Intern Med
2013;159:698-708.
39 Reid DM, Doughty J, Eastell R, Heys SD, Howell A, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008;34(Suppl 1):S3-18.
40 Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 2012;134:875-80.
 

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022